Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors

Lorenzo Bello, Carlo Giussani, Giorgio Carrabba, Mauro Pluderi, Valeria Lucini, Marilou Pannacci, Dario Caronzolo, Giustino Tomei, Roberto Villani, Francesco Scaglione, Rona S. Carroll, Andreas Bikfalvi

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Glioma recurrences develop at the borders of the surgical cavity and are the main cause of their poor prognosis. There are no therapeutic advances to reduce the incidence of recurrence or animal models that closely mimic the clinical scenario to evaluate novel therapeutics. This work investigates the efficacy of endogenous inhibitors, in preventing the recurrence of human malignant gliomas, in a newly developed animal model of glioma surgical resection. We developed a nude mice model in which human glioma xenografts were microsurgically removed. After surgery, small islets of tumor cells persisted in the normal brain parenchyma, grew, and formed a recurrence. As inhibitors we used PEX and a fragment of platelet factor 4 (PF-4/CTF), which were administered systemically on a daily basis or in metronomic combination with chemotherapy for 120 days. Treatment was started 1 or 15 days after tumor removal. PEX or PF-4/CTF produced a significant improvement in survival, and delayed the appearance of glioma recurrence. Survival of animals that received daily PEX or PF-4/CTF was similar to that of animals that received metronomic PEX or PF-4/ CTF and chemotherapy, respectively. The effect of treatment was dependent on the time at which the treatment was initiated. The highest level of inhibition was observed when the treatment was administered 1 day after surgical resection and when PEX was used as the inhibitor (120 days versus 35 days of the control). Tumors treated with PEX or PF-4/CTF were small and well delineated, with few vessels. Postsurgical administration of PEX or PF-4/CTF significantly reduces the incidence human malignant glioma recurrences for a long period of time.

Original languageEnglish
Pages (from-to)3539-3548
Number of pages10
JournalClinical Cancer Research
Volume8
Issue number11
Publication statusPublished - Nov 1 2002

Fingerprint

Glioma
Animal Models
Recurrence
Therapeutics
Islet Cell Adenoma
Platelet Factor 4
Incidence
Combination Drug Therapy
Heterografts
Nude Mice
Neoplasms
Drug Therapy
Survival
Brain

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. / Bello, Lorenzo; Giussani, Carlo; Carrabba, Giorgio; Pluderi, Mauro; Lucini, Valeria; Pannacci, Marilou; Caronzolo, Dario; Tomei, Giustino; Villani, Roberto; Scaglione, Francesco; Carroll, Rona S.; Bikfalvi, Andreas.

In: Clinical Cancer Research, Vol. 8, No. 11, 01.11.2002, p. 3539-3548.

Research output: Contribution to journalArticle

Bello, L, Giussani, C, Carrabba, G, Pluderi, M, Lucini, V, Pannacci, M, Caronzolo, D, Tomei, G, Villani, R, Scaglione, F, Carroll, RS & Bikfalvi, A 2002, 'Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors', Clinical Cancer Research, vol. 8, no. 11, pp. 3539-3548.
Bello, Lorenzo ; Giussani, Carlo ; Carrabba, Giorgio ; Pluderi, Mauro ; Lucini, Valeria ; Pannacci, Marilou ; Caronzolo, Dario ; Tomei, Giustino ; Villani, Roberto ; Scaglione, Francesco ; Carroll, Rona S. ; Bikfalvi, Andreas. / Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 11. pp. 3539-3548.
@article{917eaf7b5b304dc3867f0b0547a2836d,
title = "Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors",
abstract = "Glioma recurrences develop at the borders of the surgical cavity and are the main cause of their poor prognosis. There are no therapeutic advances to reduce the incidence of recurrence or animal models that closely mimic the clinical scenario to evaluate novel therapeutics. This work investigates the efficacy of endogenous inhibitors, in preventing the recurrence of human malignant gliomas, in a newly developed animal model of glioma surgical resection. We developed a nude mice model in which human glioma xenografts were microsurgically removed. After surgery, small islets of tumor cells persisted in the normal brain parenchyma, grew, and formed a recurrence. As inhibitors we used PEX and a fragment of platelet factor 4 (PF-4/CTF), which were administered systemically on a daily basis or in metronomic combination with chemotherapy for 120 days. Treatment was started 1 or 15 days after tumor removal. PEX or PF-4/CTF produced a significant improvement in survival, and delayed the appearance of glioma recurrence. Survival of animals that received daily PEX or PF-4/CTF was similar to that of animals that received metronomic PEX or PF-4/ CTF and chemotherapy, respectively. The effect of treatment was dependent on the time at which the treatment was initiated. The highest level of inhibition was observed when the treatment was administered 1 day after surgical resection and when PEX was used as the inhibitor (120 days versus 35 days of the control). Tumors treated with PEX or PF-4/CTF were small and well delineated, with few vessels. Postsurgical administration of PEX or PF-4/CTF significantly reduces the incidence human malignant glioma recurrences for a long period of time.",
author = "Lorenzo Bello and Carlo Giussani and Giorgio Carrabba and Mauro Pluderi and Valeria Lucini and Marilou Pannacci and Dario Caronzolo and Giustino Tomei and Roberto Villani and Francesco Scaglione and Carroll, {Rona S.} and Andreas Bikfalvi",
year = "2002",
month = "11",
day = "1",
language = "English",
volume = "8",
pages = "3539--3548",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors

AU - Bello, Lorenzo

AU - Giussani, Carlo

AU - Carrabba, Giorgio

AU - Pluderi, Mauro

AU - Lucini, Valeria

AU - Pannacci, Marilou

AU - Caronzolo, Dario

AU - Tomei, Giustino

AU - Villani, Roberto

AU - Scaglione, Francesco

AU - Carroll, Rona S.

AU - Bikfalvi, Andreas

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Glioma recurrences develop at the borders of the surgical cavity and are the main cause of their poor prognosis. There are no therapeutic advances to reduce the incidence of recurrence or animal models that closely mimic the clinical scenario to evaluate novel therapeutics. This work investigates the efficacy of endogenous inhibitors, in preventing the recurrence of human malignant gliomas, in a newly developed animal model of glioma surgical resection. We developed a nude mice model in which human glioma xenografts were microsurgically removed. After surgery, small islets of tumor cells persisted in the normal brain parenchyma, grew, and formed a recurrence. As inhibitors we used PEX and a fragment of platelet factor 4 (PF-4/CTF), which were administered systemically on a daily basis or in metronomic combination with chemotherapy for 120 days. Treatment was started 1 or 15 days after tumor removal. PEX or PF-4/CTF produced a significant improvement in survival, and delayed the appearance of glioma recurrence. Survival of animals that received daily PEX or PF-4/CTF was similar to that of animals that received metronomic PEX or PF-4/ CTF and chemotherapy, respectively. The effect of treatment was dependent on the time at which the treatment was initiated. The highest level of inhibition was observed when the treatment was administered 1 day after surgical resection and when PEX was used as the inhibitor (120 days versus 35 days of the control). Tumors treated with PEX or PF-4/CTF were small and well delineated, with few vessels. Postsurgical administration of PEX or PF-4/CTF significantly reduces the incidence human malignant glioma recurrences for a long period of time.

AB - Glioma recurrences develop at the borders of the surgical cavity and are the main cause of their poor prognosis. There are no therapeutic advances to reduce the incidence of recurrence or animal models that closely mimic the clinical scenario to evaluate novel therapeutics. This work investigates the efficacy of endogenous inhibitors, in preventing the recurrence of human malignant gliomas, in a newly developed animal model of glioma surgical resection. We developed a nude mice model in which human glioma xenografts were microsurgically removed. After surgery, small islets of tumor cells persisted in the normal brain parenchyma, grew, and formed a recurrence. As inhibitors we used PEX and a fragment of platelet factor 4 (PF-4/CTF), which were administered systemically on a daily basis or in metronomic combination with chemotherapy for 120 days. Treatment was started 1 or 15 days after tumor removal. PEX or PF-4/CTF produced a significant improvement in survival, and delayed the appearance of glioma recurrence. Survival of animals that received daily PEX or PF-4/CTF was similar to that of animals that received metronomic PEX or PF-4/ CTF and chemotherapy, respectively. The effect of treatment was dependent on the time at which the treatment was initiated. The highest level of inhibition was observed when the treatment was administered 1 day after surgical resection and when PEX was used as the inhibitor (120 days versus 35 days of the control). Tumors treated with PEX or PF-4/CTF were small and well delineated, with few vessels. Postsurgical administration of PEX or PF-4/CTF significantly reduces the incidence human malignant glioma recurrences for a long period of time.

UR - http://www.scopus.com/inward/record.url?scp=0036847733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036847733&partnerID=8YFLogxK

M3 - Article

C2 - 12429645

AN - SCOPUS:0036847733

VL - 8

SP - 3539

EP - 3548

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -